Gilead Sciences Inc. (GILD) announced Friday morning that the majority of hepatitis C genotype 1 patients with a prior "null" response to an interferon-containing regimen enrolled in the ongoing ELECTRON study experienced viral relapse within four weeks of completing 12 weeks of treatment with GS-7977 plus ribavirin.
Gilead Sciences has gapped open sharply lower Friday and is now down 8.81 at $46.00 on above average volume. The stock has dropped below a range at the highs of the year and has set a one-month low.
by RTT Staff Writer
For comments and feedback: email@example.com